Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888178 | 0.87 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL1882523 | 0.85 | PIK3CD (0.40) | PIK3CDGAAMAPTADORA2AADORA1 | |
| SCHEMBL1880629 | 0.83 | PIK3CD (0.54) | PIK3CDADORA2AADORA1 | |
| SCHEMBL1883982 | 0.81 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL1891096 | 0.77 | PIK3CD (0.44) | PIK3CDADORA2AADORA1 | |
| SCHEMBL1878979 | 0.77 | MEN1 (0.43) | PIK3CDGAAMAPTTP53GPBAR1 | |
| SCHEMBL1885110 | 0.77 | GPBAR1 (0.42) | PIK3CDGAAMAPTTP53GPBAR1 | |
| SCHEMBL1883858 | 0.76 | PIK3CD (0.41) | PIK3CDADORA2AADORA1 | |
| SCHEMBL1886855 | 0.75 | PLAU (0.39) | ADORA2AADORA1 | |
| SCHEMBL14768337 | 0.72 | GAA (0.38) | PIK3CDGAAMAPTADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885GAA 1142/4885MAPT 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.